Lege Artis Medicinae

[The sensor-augmented insulin pump and its use in clinical practice]

KÁNTOR Irén

NOVEMBER 22, 2012

Lege Artis Medicinae - 2012;22(10-11)

[Diabetes is one of the most common chronic diseases. Technological advances provide increasingly refined tools for clinicians to manage type 1 and type 2 diabetes. Continuous subcutaneous insulin infusion (CSII), also known as insulin pump, allows for a sophisticated delivery of basal as well as bolus insulin. Continuous glucose monitoring helps patients and clinicians understand and manage changes in blood glucose trends and minute-to-minute blood glucose variablitiy. The sensor-augmented insulin pump was created by the merging of these devices, which has been a revolutionary step towards self-regulatory, closed-loop insulin delivery or the creation of an artificial pancreas.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The role of the DPP-4 inhibitor sitagliptin in the therapy of type 2 diabetes, in light of the new guidelines]

HIDVÉGI Tibor

[Type 2 diabetes has become a global public health problem, threatening the economies of all nations, as a consequence of rapid urbanisation, changing eating habits, sedentary lifestyle and obesity. Asian populations tend to develop diabetes at younger ages and lower body mass index compared with Caucasians. The latest guidelines of the American Diabetes Association and the European Association for the Study of Diabetes recommend lifestyle interventions as the first step for patients with newly diagnosed type 2 diabetes. The widely used metformin remains one of the first-line drugs for type 2 diabetes. If monotherapy alone does not achieve or maintain the target HbA1c level, addition of a second oral agent is recommended as a second step. The highly selective dipetidyl peptidase-4 inhibitor sitagliptin and metformin are efficient and well tolerable. The complementary effects of sitagliptin and metformin lead to an efficient, safe and long-term improvement in glycaemic control.]

Lege Artis Medicinae

[Picturing Birth in 20th and 21st Century Graphic Arts ]

SZABÓ András

Lege Artis Medicinae

[Effect of nebivolol and carvedilol on left ventricular function and exercise capacity]

LIPTÁK Judit

Lege Artis Medicinae

[Spiritualism in Medicine: a Benefit or a Hindrance? – Remembering Mária Kopp ]

PIKÓ Bettina

Lege Artis Medicinae

[Elastofibroma]

KRUTSAY Miklós

All articles in the issue

Related contents

Hypertension and nephrology

[Deeper analysis of nebivolol effects]

KÉKES Ede

[Author presents the formation of nitric oxide as a largest vasodilator of human endothelium as well as the endothelial dysfunction a result of formation at adrenergic stimulus. He demonstrates in detail the benefits of selective β-1 blocker and β-3 adrenergic agonist nebivolol in the vascular system. This drug has also receptor independent effects. Complex effects of nebivolol causes vasodilation, inhibits oxidative stress and it is capable to neutralize the effects of free oxygen radicals and as a result the endothelial function will be better. Its clinical effects and the less wellknown beneficial properties are listed. The use of drug is discussed especially in hypertensives with smoking, COPD or PAD. The β-3 agonist effect provides positive reactions not only in the adipocytes and the myocardial tissue. but in the skeletal muscle as well: Increase in energy expenditure - as a compensatory mechanism - is increased in obesity and the glucose uptake + storage on skeletal muscle cells are increased in hyperglycemia. The insulin sensitivity will be better, leptin level is decreased, adiponectin level is increased by nebivolol. It is assumed this drug has antidiabetic and anti-obesity effects.]

Clinical Oncology

[Oncological treatment on certain special cases]

FUTÓ Ildikó, HORVÁTH Dorottya Katalin, LANDHERR László

[Even in the absence of clinically signifi cant co-morbidities, cancer care is a major challenge for both patients and healthcare professionals. Routine anticancer treatment may be complicated by special clinical situations such as pregnancy or organ transplantation. The dosage of certain oncotherapy agents may be further affected by impaired renal and hepatic function or diabetes mellitus. These days, given the improved prognosis of cancerous diseases and increased survival, personalized therapy and prevention of long-term side effects is becoming particularly important, especially in the above-mentioned oncological situations. In this summary, we review the anticancer treatments recommended by ESMO in specifi c clinical situations.]

Hypertension and nephrology

[Treatment of high blood pressure in praxis and beyond. Hypertension praxis model]

ÁDÁM Ágnes

[Author presents a hypertension care model in the general praxis. Hypertensive patients and those with diabetes, hyperlipidemia and obesity, OSAS and the therapeutic results with these care model system for three years was analysed. The target blood pressure was achieved in a great rate in all patient’s groups. the elements of therapeutic success was analysed.]

Lege Artis Medicinae

[THE VALUE OF RENAL BIOPSY IN DIABETES]

NAGY Judit, DEGRELL Péter, EKNOYAN Garabed, WITTMANN István

[The relentless increase of patients with kidney failure requiring renal replacement therapy has been documented world-wide. Recently, diabetic renal diseases has become the major cause of end-stage renal disease in the United States and in western Europe and is forecasted to become the most frequent cause of end-stage renal disease in Hungary. The most common renal lesion in type 1 as well as in type 2 diabetes is diabetic nephropathy. However, in the last few years numerous studies have demonstrated that there is a difference between patients with type 1 and those with type 2 diabetes in the expression and frequency of their renal disease. In type 1 diabetes a histological examination should only be made when a patient has features atypical of diabetic nephropathy and the indications of renal biopsy are well known. At the same time there is no agreement on renal biopsy indications in type 2 diabetes. In this review, we will summarise the characteristic features of diabetic nephropathy and other kidney alterations in the diabetic patient. Furthermore, we will raise the question of the renal biopsy indications and the more extensive use of the renal biopsy in type 2 diabetic patients for more effective prevention and treatment strategies.]

Lege Artis Medicinae

[A new DPP-IV inhibitor: saxagliptin]

KIS János Tibor, MÉSZÁROS Gabriella

[Saxagliptin is a selective, potent inhibitor of dipeptidyl peptidase-IV (DPP-IV). By inhibiting DPP-IV, saxagliptin reduces the degradation of endogenous incretin hormones, resulting in increased glucose-dependent insulin and decreased glucagon secretion from the pancreas islets. Clinical trials of saxagliptin as monotherapy and as combination therapy with other oral antidiabetic medications including metformin, glibenclamide, glipizide, pioglitazone and rosiglitazone have demonstrated clinical benefits in different glycaemic endpoints. Due to its glucose- dependent mechanism of action, saxagliptin as monotherapy or in combination with metformin results in a very low risk for hypoglycemia. It has also been shown to be generally well-tolerated, with not having any relevant effect on weight. The authors summarize the most important saxagliptin trials.]